Imperial College London

DrSarahBlagden

Faculty of MedicineDepartment of Surgery & Cancer

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

s.blagden

 
 
//

Location

 

Cyclotron buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Slusarczyk:2014:10.1021/jm401853a,
author = {Slusarczyk, M and Lopez, MH and Balzarini, J and Mason, M and Jiang, WG and Blagden, S and Thompson, E and Ghazaly, E and McGuigan, C},
doi = {10.1021/jm401853a},
journal = {JOURNAL OF MEDICINAL CHEMISTRY},
pages = {1531--1542},
title = {Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development},
url = {http://dx.doi.org/10.1021/jm401853a},
volume = {57},
year = {2014}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Slusarczyk,M
AU - Lopez,MH
AU - Balzarini,J
AU - Mason,M
AU - Jiang,WG
AU - Blagden,S
AU - Thompson,E
AU - Ghazaly,E
AU - McGuigan,C
DO - 10.1021/jm401853a
EP - 1542
PY - 2014///
SN - 0022-2623
SP - 1531
TI - Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
T2 - JOURNAL OF MEDICINAL CHEMISTRY
UR - http://dx.doi.org/10.1021/jm401853a
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000332187700029&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL - 57
ER -